Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.230
-0.040 (-1.76%)
At close: Oct 29, 2026, 4:00 PM EDT
2.300
+0.070 (3.14%)
Pre-market: Oct 30, 2026, 8:29 AM EDT
Veru Inc. Employees
Veru Inc. had 20 employees as of September 30, 2025. The number of employees decreased by 190 or 90.48% compared to the previous year. That makes Veru Inc. the 38,439th largest employer in the world and 5,537th in the United States.
Employees
20
Change (1Y)
-190
Growth (1Y)
-90.48%
Revenue / Employee
n/a
Profits / Employee
-$680,428
Market Cap
38.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 20 | -190 | -90.48% | 20 | 0 |
| Sep 30, 2024 | 210 | 21 | 11.11% | 210 | 0 |
| Sep 30, 2023 | 189 | -44 | -18.88% | 189 | 0 |
| Sep 30, 2022 | 233 | -19 | -7.54% | 233 | 0 |
| Sep 30, 2021 | 252 | -87 | -25.66% | 252 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| eXoZymes | 32 |
| Serina Therapeutics | 16 |
| Alterity Therapeutics | 11 |
| Dogwood Therapeutics | 8 |
| NanoViricides | 7 |
| Aldeyra Therapeutics | 6 |
| Grace Therapeutics | 5 |
VERU News
- 23 days ago - Veru initiated with a Buy at WestPark Capital - TheFly
- 7 weeks ago - Veru Inc. Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Veru Inc. Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Filings
- 7 weeks ago - Veru adavances sabizabulin following preclinical data - TheFly
- 7 weeks ago - Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - GlobeNewsWire
- 1 month ago - Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Veru Inc. Earnings Call Transcript: Q3 2026 - Transcripts
- 2 months ago - Veru Inc. Earnings release: Q3 2026 - Filings